

SPONSORSHIP AGREEMENT



Parties to this agreement:

Diabetes Foreningen
Att.: Eva Tingkær
Stationsparken 24, st. tv.
2600 Glostrup
CVR No. 35231528

Novo Nordisk Denmark A/S
Att.: Markus Peter Hochmuth
Kay Fiskers Plads 10, 7 floor
2300 København S
CVR No. 38180045

(“Recipient”)

(“Novo Nordisk”)

1. Summary

1.1 Recipient’s request for support. The appendix titled “Recipient’s request for support” details the specifics of the Recipient’s activity(ies) (“the Activity”) supported by the sponsorship and purpose of the Activity.

Title of Activity	Sundhedspolitik åbningsdebat Christiansborg 26. September 2023
The Sponsorship	<p>Novo Nordisk will provide DKK 75.000 to support the Recipient’s request.</p> <p>Novo Nordisk will not make any non-financial transfers of value.</p> <p>In exchange for the sponsorship, the Recipient shall provide to Novo Nordisk the tangible benefit of: mentioned as sponsor.</p> <p>Novo Nordisk is the one of several sponsors of the activity</p>
Agreement Duration	This agreement starts on 26. September 2023 and expires after all obligations are fulfilled, unless terminated earlier.

2. Recipient’s Duties

2.1 Compliance with law and ethics. The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

2.2 Carry out the Activity with proper conduct. The Recipient shall carry out the Activity independently and in compliance with Novo Nordisk standards and industry codes, in Denmark called ENLI (Etisk nævn for lægemiddelindustrien).

No use of funds for entertainment	Do not use the sponsorship for leisure or social activities
Select qualified participants	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity
Reasonable payment and awards	If sponsorship is used for awards or other payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as ‘HCPs’) and patients
Reasonable choice of venue	Hold activities in a location suitable for the Activity with modest hospitality
Reasonable travel	If sponsorship is used for Activity-related travel, carry out within reasonable time and cost

- 2.3 Physical items provided as-is.** If Novo Nordisk donates physical items, the Recipient is solely responsible for the use of such items, and shall assure proper handling and storage of sponsored items after delivery. Novo Nordisk is not liable for the Recipient's use of sponsored items and is not required to carry insurance or take any other measures to protect sponsored items after delivery. Novo Nordisk provides such items as-is and without any representation or warranty of quality or performance.
- 2.4 Internal approvals.** The Recipient shall obtain all necessary approvals related to the receipt of the sponsorship.
- 2.5 Inform Novo Nordisk of changes.** The Recipient shall inform Novo Nordisk of any changes affecting the request for support. If Novo Nordisk determines the change affects its compliance requirements, Novo Nordisk may demand full or partial return of sponsorship, at the discretion of Novo Nordisk. In the case of return, the Recipient shall comply within 14 days.
- 2.6 Provide documentation within 1 month.** The Recipient shall provide Novo Nordisk with documentation that the sponsorship was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.
- 2.7 Disclose Novo Nordisk as sponsorship provider.** The Recipient shall mention Novo Nordisk as the provider of the sponsorship in any public communications or advertising related to the Activity.
- 2.8 Do not use Novo Nordisk branding without approval.** The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.
- 2.9 Allow Novo Nordisk to use Recipient's logo.** The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's sponsorship.

3. Requirements for Financial Sponsorships

- 3.1 Payment after receipt of invoice.** Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: AP-Novo-Repas@novonordisk.com. Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Sponsorship amount payable
- VAT or other tax amount payable
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient Mona Rosenblad RNDG@novonordisk.com

- 3.2 Refund unspent amounts.** The Recipient shall refund to Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

4. Other Terms and Conditions

- 4.1 Require Public disclosures.** To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals ("HCPs"), Healthcare Organizations ("HCOs"), and Patient Organizations. In addition to the payment amount, such disclosure may also include Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.

The Recipient will publish information on the Sponsorship on the Recipient's webpage. The information will include the Sponsorship amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Sponsorship. The information must be publicly available for at least two (2) years.

- 4.2 No incentive to prescribe or recommend.** The sponsorship made by Novo Nordisk indicates no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk's products or services.

Sponsorship Agreement, DK, 2022-DEC

Local Adaptation of HQ Sponsorship Agreement v2

July 2021

- 4.3 No conflict of interest.** Recipient states it is not aware of any conflict of interest related to its acceptance of the sponsorship and shall promptly inform Novo Nordisk if such conflict of interest is discovered.
- 4.4 Compliance hotline.** The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](https://www.novonordisk.com).
- 4.5 Termination for breach.** Either party may terminate this contract immediately upon material breach by the other party.
- 4.6 Governing Law and Dispute Resolution.** The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.

5. Attachments: The following attachments are part of this agreement:

6.

Ansøgning om støtte til Christiansborg-konference

Diabetesforeningen har søsat en ny tradition: Sundhedspolitisk Åbningsdebat, som er en sundhedspolitisk konference, der gentages én gang årligt. Formålet med konferencen er at sætte rammen om den sundhedspolitiske debat som optakt til et nyt folketingsår. Afsættet for konferencen er kronikerområdet og i år vil strukturkommissionen være det aktuelle tema, vi stiller skarpt på herunder give Diabetesforeningens input til det gode patientforløb og dermed strukturer.

Strukturkommissionen har blandt andet til opgave at finde løsninger på bedre samspil og forløb for de store kronikergrupper. Med 1,2 millioner danskere med kronisk sygdom – heraf 356.000 med diabetes er der behov for handling for bedre forløb og et løft af behandlingen ikke mindst for at mindske presset på sundhedsvæsenet.

Praktisk:

Konferencen afholdes den **26. september 2023 på Christiansborg** og Monika Rubin, MF for Moderaterne er vært for konferencen. Herudover forventes bred deltagelse af sundhedsordførere.

Det endelige program er under udarbejdelse, oplægsholderne på konferencen vil være eksperter, ministre, og politikere fra hhv. regioner og kommuner, embedsmænd, organisationer eller andre med fremtrædende roller på sundhedsfeltet. Og der afsøges oplægsholdere og input fra andre patientforeninger for at have en bred inddragelse af patientperspektivet.

7.

Stationsparken 24, st. tv.
2600 Glostrup

Telefon 66 12 90 06
Fax 65 91 49 08
info@diabetes.dk
www.diabetes.dk

CVR-nr. DK-35 23 15 28

Attachment A: Recipient's request for support (application form, letter or email)

Økonomi

Diabetesforeningen anmoder Novo Nordisk om et sponsorat på **75.000 kr.**

Den finansielle ydelse skal bruges til at dække en del af Diabetesforeningens udgifter i forbindelse med konferencen samt udgifter til delvis moms (Diabetesforeningen har kun mulighed for at trække 19,2 % af momsdelen fra vores udgifter).

Udgift	Estimeret pris (ekskl. Moms)
Moderator	20.000 kr.
Transport og honorarer til enkelte oplægsholdere	10.000 kr.
Trykomsstninger	20.000 kr.
Udgifter til moms	10.000 kr.
I alt	<u>60.000 kr.</u>

8. Agreed to and Accepted by:

Date: august 29, 2023

On behalf of Recipient:

DocuSigned by:
Eva Tingkær
310CDEAFA3DD483

Name: Eva Tingkær

Title: Head of Public Affairs

Date: August 29, 2023

On behalf of Novo Nordisk:

DocuSigned by:
Markus Peter Hochmuth
D6C3B77D06B64DC

Name: Markus Peter Hochmuth

Title: Senior MAPA Director

Date: August 29, 2023

On behalf of Novo Nordisk:

DocuSigned by:
Jeppe Theisen
8517A55EC9C4433...

Title: General Manager

Jeppe Theisen

Attachment A: Recipient's Request for Support

1. Copy of the Recipient's sponsorship request

Ansøgning om støtte til Christiansborg-konference

Diabetesforeningen har søsat en ny tradition: Sundhedspolitisk Åbningsdebat, som er en sundhedspolitisk konference, der gentages én gang årligt. Formålet med konferencen er at sætte rammen om den sundhedspolitiske debat som optakt til et nyt folketingsår. Afsættet for konferencen er kronikerområdet og i år vil strukturkommissionen være det aktuelle tema, vi stiller skarpt på herunder give Diabetesforeningens input til det gode patientforløb og dermed strukturer.

Strukturkommissionen har blandt andet til opgave at finde løsninger på bedre samspil og forløb for de store kronikergrupper. Med 1,2 millioner danskere med kronisk sygdom – heraf 356.000 med diabetes er der behov for handling for bedre forløb og et løft af behandlingen ikke mindst for at mindske presset på sundhedsvæsnet.

Praktisk:

Konferencen afholdes den **26. september 2023 på Christiansborg** og Monika Rubin, MF for Moderaterne er vært for konferencen. Herudover forventes bred deltagelse af sundhedsordførere.

Det endelige program er under udarbejdelse, oplægsholderne på konferencen vil være eksperter, ministre, og politikere fra hhv. regioner og kommuner, embedsmænd, organisationer eller andre med fremtrædende roller på sundhedsfeltet. Og der afsøges oplægsholdere og input fra andre patientforeninger for at have en bred inddragelse af patientperspektivet.

Stationsparken 24, st. tv.
2600 Glostrup

Telefon 66 12 90 06
Fax 65 91 49 08
info@diabetes.dk
www.diabetes.dk

CVR-nr. DK-35 23 15 28

2. Activity timelines and budget

Økonomi

Diabetesforeningen anmoder Novo Nordisk om et sponsorat på **75.000 kr.**

Den finansielle ydelse skal bruges til at dække en del af Diabetesforeningens udgifter i forbindelse med konferencen samt udgifter til delvis moms (Diabetesforeningen har kun mulighed for at trække 19,2 % af momsdelen fra vores udgifter).

Udgift	Estimeret pris (ekskl. Moms)
Moderator	20.000 kr.
Transport og honorarer til enkelte oplægsholdere	10.000 kr.
Trykomsstninger	20.000 kr.
Udgifter til moms	10.000 kr.
I alt	<u>60.000 kr.</u>